Brett Staahl and Benjamin Oakes
October 6, 2020 10:38 AM EDTUpdated October 8, 04:05 PM
People
Startups

The lat­est Jen­nifer Doud­na start­up launch­es with a Bio­gen part­ner­ship and eyes on big tar­gets few CRISPR com­pa­nies have chased

Jason Mast

Editor

Three years ago, Jen­nifer Doud­na gath­ered with two post­docs and a fel­low bio­chemist around a cir­cu­lar ta­ble on the sec­ond floor of UC Berke­ly’s En­er­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times